Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsubara, Y.
Right arrow Articles by Mashimo, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsubara, Y.
Right arrow Articles by Mashimo, T.
(Chest. 2005;128:3519-3525.)
© 2005 American College of Chest Physicians

Risk Stratification for Lung Cancer Surgery*

Impact of Induction Therapy and Extended Resection

Yoko Matsubara, MD; Shin-ichi Takeda, MD, FCCP and Takashi Mashimo, MD, PhD

* From the Departments of Anesthesiology (Dr. Matsubara) and General Thoracic Surgery (Dr. Takeda), Toneyama National Hospital, Toyonaka City, Osaka, Japan; and the Department of Acute Critical Medicine (Anesthesiology) [Dr. Mashimo], Osaka University Graduate School of Medicine, Suita City, Osaka, Japan.

Correspondence to: Shin-ichi Takeda, MD, FCCP, Toneyama National Hospital, Toneyama 5–1-1, Toyonaka 560-8552, Japan; e mail: stakeda{at}toneyama.hosp.go.jp

Study objectives: Current surgical strategies for lung cancer are directed toward the following two distinct targets: the increased prevalence of early-stage lung cancer; and locally advanced lung cancer treated with induction therapy (IT). To establish the risk stratification for operative morbidity from this viewpoint, we evaluated the impact of IT and/or an extended surgical procedure on operative results.

Design: Retrospective study.

Setting: A 674-bed teaching hospital.

Patients and methods: The morbidity and mortality of 758 consecutive patients who underwent surgery for the treatment of non-small cell lung cancer were analyzed. There were 666 patients who underwent surgery alone (S group; 560 standard lobectomies and 106 extended resections) and 92 patients who received IT (IT group; 35 standard lobectomies and 57 extended resections). Comparisons between the groups were performed using unpaired t tests or {chi}2 tests. Univariate and multivariate logistic regression analyses were used to determine the risk factors for operative morbidity and mortality.

Results: IT and extended surgery were strong independent factors for predicting postoperative morbidity (p < 0.0001). Significant differences were observed for pathologic stage (p < 0.0001), preoperative hemoglobin and DLCO levels (p < 0.001), the ratio of extended resection (p < 0.0001), and operation time and intraoperative bleeding (p < 0.001) between the S and IT groups. The overall morbidity and mortality rates were 16.8% and 0.9%, respectively, in the S group, and 55.4% and 5.4%, respectively, in the IT group (p < 0.01). The overall morbidity and mortality rates were 63.2% and 7.0%, respectively, for extended resection after IT, and 12.8% and 0.3%, respectively, for those who underwent a standard resection without IT.

Conclusions: The morbidity and mortality of lung resection are both significantly increased after IT, and the patients with the greatest risk are those who have undergone IT and extended resection. The impact of IT on risk stratification should be emphasized in perioperative care.

Key Words: extended surgery • induction therapy • lung cancer • pulmonary resection • risk stratification




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
Z. Mansour, E. A. Kochetkova, X. Ducrocq, M.-D. Vasilescu, G. Maxant, A. Buggenhout, J.-M. Wihlm, and G. Massard
Induction chemotherapy does not increase the operative risk of pneumonectomy!
Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 181 - 185.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S.-i. Takeda, Y. Funakoshi, Y. Kadota, M. Koma, H. Maeda, S. Kawamura, and Y. Matsubara
Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complication?
Ann. Thorac. Surg., July 1, 2006; 82(1): 232 - 236.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
S.-i. Takeda, H. Maeda, T. Okada, T. Yamaguchi, M. Nakagawa, S. Yokota, N. Sawabata, and M. Ohta
Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA-IIIB) lung cancer.
Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 184 - 189.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
S.-i. Takeda, H. Maeda, M. Koma, Y. Matsubara, N. Sawabata, M. Inoue, T. Tokunaga, and M. Ohta
Comparison of surgical results after pneumonectomy and sleeve lobectomy for non-small cell lung cancer.: Trends over time and 20-year institutional experience
Eur. J. Cardiothorac. Surg., March 1, 2006; 29(3): 276 - 280.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Chest Physicians.